Loading…

Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function

Background. Renin–angiotensin–aldosterone system (RAAS) blockade improves prognosis in renal patients, but usually requires diuretic co-treatment. RAAS blockade can decrease erythropoietin (EPO) and/or haemoglobin (Hb) levels. Diuretics decrease EPO in rodents, but their effect on EPO and Hb in huma...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 2010-10, Vol.25 (10), p.3256-3260
Main Authors: Slagman, Maartje C.J., Sinkeler, Steef J., Hemmelder, Marc H., Waanders, Femke, Vogt, Liffert, Kluin-Nelemans, Hanneke C., Navis, Gerjan, Laverman, Gozewijn D.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433
cites cdi_FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433
container_end_page 3260
container_issue 10
container_start_page 3256
container_title Nephrology, dialysis, transplantation
container_volume 25
creator Slagman, Maartje C.J.
Sinkeler, Steef J.
Hemmelder, Marc H.
Waanders, Femke
Vogt, Liffert
Kluin-Nelemans, Hanneke C.
Navis, Gerjan
Laverman, Gozewijn D.
description Background. Renin–angiotensin–aldosterone system (RAAS) blockade improves prognosis in renal patients, but usually requires diuretic co-treatment. RAAS blockade can decrease erythropoietin (EPO) and/or haemoglobin (Hb) levels. Diuretics decrease EPO in rodents, but their effect on EPO and Hb in humans is unknown. Methods. Proteinuric renal patients with preserved renal function were treated during 6-week periods with placebo, losartan 100 mg/day (LOS) and LOS plus hydrochlorothiazide 25 mg/day (LOS/HCT), in random order. Results. Hb was inversely related to proteinuria, and EPO levels were inappropriately low in relation to Hb. Hb was lowered by LOS with and without HCT. EPO was decreased by LOS/HCT, but not by LOS. Conclusions. EPO and Hb are reduced by HCT added to LOS in proteinuric renal patients with preserved renal function. We hypothesize that EPO reduction by HCT is caused by a decrease in renal oxygen requirement, which is the main stimulus for EPO production, due to the inhibition of active tubular sodium reabsorption. Further studies should explore the exact mechanism of this phenomenon and its clinical impact.
doi_str_mv 10.1093/ndt/gfq149
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_755174677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>755174677</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433</originalsourceid><addsrcrecordid>eNpFkM1uFDEQhC1ERJbAhQdAvqBISEPs8fz5uFqFBGklFP6E9mJ57DZrMmtPbA9hXyFPjcNsklMf6uuq7kLoDSUfKOHszOl09svc0Io_QwtaNaQoWVc_R4ss0oLUhB-jlzH-JoTwsm1foOOSMMYJ5wt0dx72aRv86C0k67CNOICeFGjc77Hyu946max32Bus7RQypXDaQpDjHkun8Zfl8ivuB6-upQacLcbgE1g3hQwGcHLAY3YAlyK-tWmbdYgQ_uSEWTWTU_cJr9CRkUOE14d5gr5_PP-2uizWny8-rZbrQuWbU6H6suJdVXeGEl0r1umaAtX5IdlA0_Gm7DsDQJtSGuAlNbTqlaK9ZErpqmLsBJ3OvvnQmwliEjsbFQyDdOCnKNq6pm3VtG0m38-kCj7GAEaMwe5k2AtKxH31Ilcv5uoz_PZgO_U70I_oQ9cZeHcAZFRyMEE6ZeMTx1hDqv-pxczZmODvoy7DtWha1tbi8udGrH5s6HpzdZXX_gHkyZ_G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>755174677</pqid></control><display><type>article</type><title>Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function</title><source>Oxford Journals Online</source><creator>Slagman, Maartje C.J. ; Sinkeler, Steef J. ; Hemmelder, Marc H. ; Waanders, Femke ; Vogt, Liffert ; Kluin-Nelemans, Hanneke C. ; Navis, Gerjan ; Laverman, Gozewijn D.</creator><creatorcontrib>Slagman, Maartje C.J. ; Sinkeler, Steef J. ; Hemmelder, Marc H. ; Waanders, Femke ; Vogt, Liffert ; Kluin-Nelemans, Hanneke C. ; Navis, Gerjan ; Laverman, Gozewijn D.</creatorcontrib><description>Background. Renin–angiotensin–aldosterone system (RAAS) blockade improves prognosis in renal patients, but usually requires diuretic co-treatment. RAAS blockade can decrease erythropoietin (EPO) and/or haemoglobin (Hb) levels. Diuretics decrease EPO in rodents, but their effect on EPO and Hb in humans is unknown. Methods. Proteinuric renal patients with preserved renal function were treated during 6-week periods with placebo, losartan 100 mg/day (LOS) and LOS plus hydrochlorothiazide 25 mg/day (LOS/HCT), in random order. Results. Hb was inversely related to proteinuria, and EPO levels were inappropriately low in relation to Hb. Hb was lowered by LOS with and without HCT. EPO was decreased by LOS/HCT, but not by LOS. Conclusions. EPO and Hb are reduced by HCT added to LOS in proteinuric renal patients with preserved renal function. We hypothesize that EPO reduction by HCT is caused by a decrease in renal oxygen requirement, which is the main stimulus for EPO production, due to the inhibition of active tubular sodium reabsorption. Further studies should explore the exact mechanism of this phenomenon and its clinical impact.</description><identifier>ISSN: 0931-0509</identifier><identifier>EISSN: 1460-2385</identifier><identifier>DOI: 10.1093/ndt/gfq149</identifier><identifier>PMID: 20339099</identifier><identifier>CODEN: NDTREA</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Angiotensin II Type 1 Receptor Blockers - administration &amp; dosage ; Biological and medical sciences ; Cross-Over Studies ; diuretics ; Diuretics - administration &amp; dosage ; Double-Blind Method ; Drug Therapy, Combination ; Emergency and intensive care: renal failure. Dialysis management ; erythropoietin ; Erythropoietin - blood ; Female ; haemoglobin ; Humans ; Hydrochlorothiazide - administration &amp; dosage ; Intensive care medicine ; Kidney - physiopathology ; Losartan - administration &amp; dosage ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; proteinuria ; Proteinuria - blood ; Proteinuria - drug therapy ; Proteinuria - physiopathology ; renal disease ; Renal failure ; renin–angiotensin–aldosterone system blockade</subject><ispartof>Nephrology, dialysis, transplantation, 2010-10, Vol.25 (10), p.3256-3260</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433</citedby><cites>FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23360477$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20339099$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Slagman, Maartje C.J.</creatorcontrib><creatorcontrib>Sinkeler, Steef J.</creatorcontrib><creatorcontrib>Hemmelder, Marc H.</creatorcontrib><creatorcontrib>Waanders, Femke</creatorcontrib><creatorcontrib>Vogt, Liffert</creatorcontrib><creatorcontrib>Kluin-Nelemans, Hanneke C.</creatorcontrib><creatorcontrib>Navis, Gerjan</creatorcontrib><creatorcontrib>Laverman, Gozewijn D.</creatorcontrib><title>Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function</title><title>Nephrology, dialysis, transplantation</title><addtitle>Nephrol Dial Transplant</addtitle><description>Background. Renin–angiotensin–aldosterone system (RAAS) blockade improves prognosis in renal patients, but usually requires diuretic co-treatment. RAAS blockade can decrease erythropoietin (EPO) and/or haemoglobin (Hb) levels. Diuretics decrease EPO in rodents, but their effect on EPO and Hb in humans is unknown. Methods. Proteinuric renal patients with preserved renal function were treated during 6-week periods with placebo, losartan 100 mg/day (LOS) and LOS plus hydrochlorothiazide 25 mg/day (LOS/HCT), in random order. Results. Hb was inversely related to proteinuria, and EPO levels were inappropriately low in relation to Hb. Hb was lowered by LOS with and without HCT. EPO was decreased by LOS/HCT, but not by LOS. Conclusions. EPO and Hb are reduced by HCT added to LOS in proteinuric renal patients with preserved renal function. We hypothesize that EPO reduction by HCT is caused by a decrease in renal oxygen requirement, which is the main stimulus for EPO production, due to the inhibition of active tubular sodium reabsorption. Further studies should explore the exact mechanism of this phenomenon and its clinical impact.</description><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Angiotensin II Type 1 Receptor Blockers - administration &amp; dosage</subject><subject>Biological and medical sciences</subject><subject>Cross-Over Studies</subject><subject>diuretics</subject><subject>Diuretics - administration &amp; dosage</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>erythropoietin</subject><subject>Erythropoietin - blood</subject><subject>Female</subject><subject>haemoglobin</subject><subject>Humans</subject><subject>Hydrochlorothiazide - administration &amp; dosage</subject><subject>Intensive care medicine</subject><subject>Kidney - physiopathology</subject><subject>Losartan - administration &amp; dosage</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>proteinuria</subject><subject>Proteinuria - blood</subject><subject>Proteinuria - drug therapy</subject><subject>Proteinuria - physiopathology</subject><subject>renal disease</subject><subject>Renal failure</subject><subject>renin–angiotensin–aldosterone system blockade</subject><issn>0931-0509</issn><issn>1460-2385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNpFkM1uFDEQhC1ERJbAhQdAvqBISEPs8fz5uFqFBGklFP6E9mJ57DZrMmtPbA9hXyFPjcNsklMf6uuq7kLoDSUfKOHszOl09svc0Io_QwtaNaQoWVc_R4ss0oLUhB-jlzH-JoTwsm1foOOSMMYJ5wt0dx72aRv86C0k67CNOICeFGjc77Hyu946max32Bus7RQypXDaQpDjHkun8Zfl8ivuB6-upQacLcbgE1g3hQwGcHLAY3YAlyK-tWmbdYgQ_uSEWTWTU_cJr9CRkUOE14d5gr5_PP-2uizWny8-rZbrQuWbU6H6suJdVXeGEl0r1umaAtX5IdlA0_Gm7DsDQJtSGuAlNbTqlaK9ZErpqmLsBJ3OvvnQmwliEjsbFQyDdOCnKNq6pm3VtG0m38-kCj7GAEaMwe5k2AtKxH31Ilcv5uoz_PZgO_U70I_oQ9cZeHcAZFRyMEE6ZeMTx1hDqv-pxczZmODvoy7DtWha1tbi8udGrH5s6HpzdZXX_gHkyZ_G</recordid><startdate>20101001</startdate><enddate>20101001</enddate><creator>Slagman, Maartje C.J.</creator><creator>Sinkeler, Steef J.</creator><creator>Hemmelder, Marc H.</creator><creator>Waanders, Femke</creator><creator>Vogt, Liffert</creator><creator>Kluin-Nelemans, Hanneke C.</creator><creator>Navis, Gerjan</creator><creator>Laverman, Gozewijn D.</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20101001</creationdate><title>Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function</title><author>Slagman, Maartje C.J. ; Sinkeler, Steef J. ; Hemmelder, Marc H. ; Waanders, Femke ; Vogt, Liffert ; Kluin-Nelemans, Hanneke C. ; Navis, Gerjan ; Laverman, Gozewijn D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Angiotensin II Type 1 Receptor Blockers - administration &amp; dosage</topic><topic>Biological and medical sciences</topic><topic>Cross-Over Studies</topic><topic>diuretics</topic><topic>Diuretics - administration &amp; dosage</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>erythropoietin</topic><topic>Erythropoietin - blood</topic><topic>Female</topic><topic>haemoglobin</topic><topic>Humans</topic><topic>Hydrochlorothiazide - administration &amp; dosage</topic><topic>Intensive care medicine</topic><topic>Kidney - physiopathology</topic><topic>Losartan - administration &amp; dosage</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>proteinuria</topic><topic>Proteinuria - blood</topic><topic>Proteinuria - drug therapy</topic><topic>Proteinuria - physiopathology</topic><topic>renal disease</topic><topic>Renal failure</topic><topic>renin–angiotensin–aldosterone system blockade</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Slagman, Maartje C.J.</creatorcontrib><creatorcontrib>Sinkeler, Steef J.</creatorcontrib><creatorcontrib>Hemmelder, Marc H.</creatorcontrib><creatorcontrib>Waanders, Femke</creatorcontrib><creatorcontrib>Vogt, Liffert</creatorcontrib><creatorcontrib>Kluin-Nelemans, Hanneke C.</creatorcontrib><creatorcontrib>Navis, Gerjan</creatorcontrib><creatorcontrib>Laverman, Gozewijn D.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nephrology, dialysis, transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Slagman, Maartje C.J.</au><au>Sinkeler, Steef J.</au><au>Hemmelder, Marc H.</au><au>Waanders, Femke</au><au>Vogt, Liffert</au><au>Kluin-Nelemans, Hanneke C.</au><au>Navis, Gerjan</au><au>Laverman, Gozewijn D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function</atitle><jtitle>Nephrology, dialysis, transplantation</jtitle><addtitle>Nephrol Dial Transplant</addtitle><date>2010-10-01</date><risdate>2010</risdate><volume>25</volume><issue>10</issue><spage>3256</spage><epage>3260</epage><pages>3256-3260</pages><issn>0931-0509</issn><eissn>1460-2385</eissn><coden>NDTREA</coden><abstract>Background. Renin–angiotensin–aldosterone system (RAAS) blockade improves prognosis in renal patients, but usually requires diuretic co-treatment. RAAS blockade can decrease erythropoietin (EPO) and/or haemoglobin (Hb) levels. Diuretics decrease EPO in rodents, but their effect on EPO and Hb in humans is unknown. Methods. Proteinuric renal patients with preserved renal function were treated during 6-week periods with placebo, losartan 100 mg/day (LOS) and LOS plus hydrochlorothiazide 25 mg/day (LOS/HCT), in random order. Results. Hb was inversely related to proteinuria, and EPO levels were inappropriately low in relation to Hb. Hb was lowered by LOS with and without HCT. EPO was decreased by LOS/HCT, but not by LOS. Conclusions. EPO and Hb are reduced by HCT added to LOS in proteinuric renal patients with preserved renal function. We hypothesize that EPO reduction by HCT is caused by a decrease in renal oxygen requirement, which is the main stimulus for EPO production, due to the inhibition of active tubular sodium reabsorption. Further studies should explore the exact mechanism of this phenomenon and its clinical impact.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>20339099</pmid><doi>10.1093/ndt/gfq149</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0931-0509
ispartof Nephrology, dialysis, transplantation, 2010-10, Vol.25 (10), p.3256-3260
issn 0931-0509
1460-2385
language eng
recordid cdi_proquest_miscellaneous_755174677
source Oxford Journals Online
subjects Adult
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Angiotensin II Type 1 Receptor Blockers - administration & dosage
Biological and medical sciences
Cross-Over Studies
diuretics
Diuretics - administration & dosage
Double-Blind Method
Drug Therapy, Combination
Emergency and intensive care: renal failure. Dialysis management
erythropoietin
Erythropoietin - blood
Female
haemoglobin
Humans
Hydrochlorothiazide - administration & dosage
Intensive care medicine
Kidney - physiopathology
Losartan - administration & dosage
Male
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
proteinuria
Proteinuria - blood
Proteinuria - drug therapy
Proteinuria - physiopathology
renal disease
Renal failure
renin–angiotensin–aldosterone system blockade
title Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A20%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erythropoietin%20is%20reduced%20by%20combination%20of%20diuretic%20therapy%20and%20RAAS%20blockade%20in%20proteinuric%20renal%20patients%20with%20preserved%20renal%20function&rft.jtitle=Nephrology,%20dialysis,%20transplantation&rft.au=Slagman,%20Maartje%20C.J.&rft.date=2010-10-01&rft.volume=25&rft.issue=10&rft.spage=3256&rft.epage=3260&rft.pages=3256-3260&rft.issn=0931-0509&rft.eissn=1460-2385&rft.coden=NDTREA&rft_id=info:doi/10.1093/ndt/gfq149&rft_dat=%3Cproquest_cross%3E755174677%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c390t-cb2498458f10d5c38d51e1d339a6e68962b8fee162afe921f14bcc1ba3ccd4433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=755174677&rft_id=info:pmid/20339099&rfr_iscdi=true